Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits

Area of Science:

• Endocrinology
• Cardiology
• Nephrology

Background:

• Type 2 diabetes mellitus frequently coexists with cardiovascular and renal diseases.
• Complications like stroke, heart attack, heart failure, and chronic kidney disease significantly increase morbidity and mortality.
• Emerging evidence suggests some antidiabetic medications provide cardioprotective and renoprotective benefits.

Purpose of the Study:

• To review non-insulin antidiabetic drugs with benefits beyond glycemic control.
• To discuss proposed mechanisms underlying these cardiovascular and renal protective effects.
• To evaluate the role of these agents in managing patients with type 2 diabetes and comorbidities.

Main Methods:

• Summarizing evidence from recent clinical trials, including EMPA-REG OUTCOME and LEADER.
• Analyzing data on major cardiovascular events, all-cause mortality, and renal replacement therapy.
• Reviewing proposed mechanisms of action for cardioprotection and renoprotection.

Main Results:

• Empagliflozin and liraglutide demonstrated significant cardiovascular and/or renal benefits in landmark trials.
• These agents led to new FDA indications for reducing major cardiovascular event risk in specific patient populations.
• Ongoing trials are investigating class effects and other agents for cardiovascular and renal risk reduction.

Conclusions:

• Certain non-insulin antidiabetic drugs offer substantial benefits beyond glycemic control.
• Empagliflozin and liraglutide have established roles in reducing cardiovascular and renal risk in type 2 diabetes.
• Further research is needed to fully elucidate class effects and expand therapeutic options.